Heggie Theresa's Form 4 filing
Biocryst Pharmaceuticals IncBCRX · filed Jun 14, 2024
- Accession no.
- 0001127602-24-018715
- Filed
- Jun 14, 2024
- Trade date
- Jun 12-14, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $40.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Heggie TheresaCIK 0001760020 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2024 | Common Stock | AGrant or awardAcquired | +6,820 | $0.00 | $0 | 59,550 | Direct | |
| Jun 14, 2024 | Common Stock | SSaleDisposed | −6,698 | $6.11F3 | −$40,924.78 | 52,852 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2024 | Common Stock | AGrant or awardAcquired | +49,933 | $0.00 | $0 | 49,933 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.08 to $6.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.